Prevalence and risk factors of hearing loss in children with solid tumors treated with platinum-based chemotherapy

Abstract

Background The platinum-based chemotherapy drugs, cisplatin and carboplatin, are widely used in the treatment of several types of solid tumors. However, the treatment has side effects including hearing loss. Objective To evaluate the prevalence of hearing loss related to platinum-based chemotherapy and to identify associated factors. Methods A cross-sectional study was performed in Adam Malik Hospital, Medan, North Sumatera, from April to July 2012. Twenty-two subjects who fulfilled the eligibility criteria underwent otoacoustic emission evaluations. Eleven children had received cisplatin and eleven had received carboplatin. The association between hearing loss and risk factors was assessed using Fisher's exact and Chi-square tests. Results Seven subjects with hearing loss were identified. Five of these patients (5 out of 11) had received cisplatin and 2 patients (2 out of 11) had received carboplatin. There was no statistically significant difference between carboplatin-and cisplatinassociated hearing loss (P=0.361). Neither gender (P=0.452) nor age (P=0.212) was related to hearing loss. However, higher cumulative chemotherapy doses (cisplatin >600 mg/m² and carboplatin >1800 mg/m²) were associated with hearing loss (P=0.022 and P=0.004, respectively). Conclusion Patients who had higher cumulative doses of platinum-based chemotherapy are at risk for developing hearing loss. [Paediatr Indones. 2015;55:121-5.].

Global burden of ototoxic hearing loss associated with platinum-based cancer treatment: A systematic review and meta-analysis

“…A total of 994 non-duplicate citations were identified by using the selected keywords. After the final review, 66 articles were eligible for inclusion in this study [27] , [28] , [29] , [30] , [31] , [32] , [33] , [34] , [35] , [36] , [37] , [38] , [39] , [40] , [41] , [42] , [43] , [44] , [45] , [46] , [47] , [48] , [49] , [50] , [51] , [52] , [53] , [54] , [55] , [56] , [57] , [58] , [59] , [60] , [61] , [62] , [63] , [64] , [65] , [66] , [67] , [68] , [69] , [70] , [71] , [72] , [73] , [74] , [75] , [76] , [77] , [78] , [79] , [80] , [81] , [82] , [83] , [84] , [85] , [86] , [87] , [88] , [89] , [90] . The study selection process is shown in Fig.…”

Kenpaullone (CDK2 Inhibitor dan GSK-3? Inhibitor) sebagai agen otoprotektif pada pasien kemoterapi berbasis cisplatin: tinjauan pustaka

“…16 DNA repair diinduksi melalui sistem nucleotide excision repair (NER), excision repair cross-complementation group 1 (ERCC1), dan xeroderma pigmentosum (XP), dimana secara bersamaan akan menggantikan kerusakan DNA selanjutnnya akan terjadi polimerase dan ligase akan terisi gap oleh DNA untai normal. 16 Menurut penelitian dari 18 Ototoksisitas yang dilaporkan terjadi pada setiap waktu, mulai dari hitungan jam hingga hari setelah kemoterapi dan ototoksisitas ini terjadi secara permanen, bilateral, dan adanya gangguan pendengaran sensorineural. 17,18 Tercatat 30 hingga 100 persen pasien kemoterapi cisplatin mengalami dampak dari efek samping khususnya gangguan pendengaran.…”

Armadillo Repeat-Containing Protein 8 (ARMC8) Silencing Inhibits Proliferation and Invasion in Osteosarcoma Cells

“…Osteosarcoma is the most common primary malignant bone tumor and a leading cause of cancer death in adolescents ( 1 ). During the last decade, several strategies have been suggested for the treatment of osteosarcoma patients, but unfortunately some patients died of pulmonary metastases ( 2–5 ). Therefore, it is urgent to explore the molecular mechanisms underlying osteosarcoma carcinogenesis and progression in order to improve the prevention and treatment of this disease.…”